Trial Profile
A multicenter, randomized, 52-week, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary) ; Indacaterol/mometasone; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms IRIDIUM
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
- 29 Jun 2023 Results of a post-hoc analysis whether baseline eosinophil levels affect efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) in patients with inadequately controlled asthma published in the Respiratory Medicine
- 09 Mar 2023 Results of post hoc analysis , assessing the efficacy of MF/IND/GLY in asthma patients with and without PAL, published in the Respiratory Medicine